Aylin Cankaya, Matthias Balzer, Holger Amthauer, Winfried Brenner, Sarah Spreckelmeyer. Optimization of Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 10
Thien Vinh Luong, Erik Nguyen Nielsen, Lise Falborg, Mette Louise Gram Kjærulff, Lars Poulsen Tolbod, Esben Søndergaard, Niels Møller, Ole Lajord Munk, Lars Christian Gormsen. Intravenous and oral whole body ketone dosimetry, biodistribution, metabolite correction and kinetics studied by (R)-[1-C]β-hydroxybutyrate ([C]OHB) PET in healthy humans.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 12
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille. First preclinical evaluation of [Ac]Ac-DOTA-JR11 and comparison with [Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 13
Mai Lin, Robert T Ta, H Charles Manning. Simplified and highly-reliable automated production of [F]FSPG for clinical studies.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 15
Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li, Eva Bezak. In vitro characterisation of [Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 18
Anders Josefsson, Angel G Cortez, Harikrishnan Rajkumar, Joseph D Latoche, Ambika P Jaswal, Kathryn E Day, Mohammadreza Zarisfi, Lora H Rigatti, Ziyu Huang, Jessie R Nedrow. Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [Ac]Ac-DOTA-TDA-Lipiodol against hepatic tumors.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 19
Romy Cools, Koen Vermeulen, Valeria Narykina, Renan C F Leitao, Guy Bormans. Radiosynthesis and preclinical evaluation of [C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 2
Taco Metelerkamp Cappenberg, Stijn De Schepper, Christel Vangestel, Stef De Lombaerde, Leonie Wyffels, Tim Van den Wyngaert, Jeffrey Mattis, Brian Gray, Koon Pak, Sigrid Stroobants, Filipe Elvas. First-in-human study of a novel cell death tracer [Tc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 20
Belinda Trachsel, Giulia Valpreda, Alexandra Lutz, Roger Schibli, Linjing Mu, Martin Béhé. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 21
Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz, Eva Bezak. Development of [Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration.EJNMMI radiopharmacy and chemistry. 2023, 8 (1): 22